2025年哮喘研究进展综述
本文综述2025年哮喘研究进展,强调哮喘的多维视角,整合疾病轨迹、急性加重风险、气道结构改变、合并症和治疗反应性。轻度哮喘证据进一步支持抗炎缓解策略优于单用SABA;重度哮喘治疗目标扩展至疾病修饰(包括减少口服激素、改善肺功能、减少黏液栓、达到临床缓解)。真实世界管理强调可治疗特征导向照护、生物标志物分层、数字吸入技术和健康公平。
要点
- 轻度哮喘支持按需吸入糖皮质激素的抗炎缓解策略,尤其在成人和青少年中。
- 重度哮喘治疗目标从减少急性加重扩展到疾病修饰与临床缓解。
- 真实世界管理强调可治疗特征、生物标志物分层与数字吸入技术。
核心结论
- 2025年哮喘研究进一步推进多维视角,整合疾病轨迹、急性加重风险、气道结构改变、合并症和治疗反应性。
- 临床缓解定义更清晰,并日益成为治疗目标和研究终点。
研究设计与样本
- 本文为叙述性综述(Contemporary Concise Review),未报告系统检索范围与样本量。
主要发现
- 轻度哮喘研究支持及时吸入糖皮质激素以减少急性加重风险,在成人和青少年中证据较强,儿童证据尚不明确。
- 重度哮喘治疗焦点扩展至口服糖皮质激素减量、肺功能改善或正常化、减少黏液栓和达到临床缓解。
- 气道上皮、炎症细胞生态、微生物组相关内型、黏液栓生物学和生命早期气道重塑起源在哮喘异质性和进展中起核心作用。
临床怎么用
- 轻度哮喘可优先考虑抗炎缓解策略而非单用SABA,在症状加重时及时给予吸入糖皮质激素。
- 重度哮喘管理可围绕疾病修饰目标,包括减少口服激素、改善肺功能、减少黏液栓和追求临床缓解。
- 真实世界实践可结合可治疗特征、生物标志物分层和数字吸入技术,并关注不同人群的健康公平。
局限性
- 本文为叙述性综述,未报告系统检索策略、纳入标准或定量合并分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Asthma research in 2025 further advanced a multidimensional view of asthma, integrating disease trajectory, exacerbation risk, structural airway changes, comorbidities, and treatment responsiveness. In mild asthma, studies published in 2025 further reinforced the importance of anti-inflammatory reliever strategies over SABA-only treatment by supporting timely inhaled corticosteroid delivery at symptom worsening to reduce exacerbation risk, particularly in adults and adolescents, while providing emerging but still nuanced evidence in child. In severe asthma, the therapeutic focus expanded beyond exacerbation reduction towards disease modification, including oral corticosteroid sparing, improvement or normalisation of lung function, reduction of mucus plugging, and attainment of clinical remission. Clinical remission became more clearly defined and increasingly positioned as a treatment target and research endpoint, supported by emerging consensus definitions, real-world data, and analyses of biologic trials. Real-world asthma management increasingly emphasised implementation, including treatable-traits-based care, biomarker-informed stratification, digital inhaler technologies, and approaches to persistent ethnic, social, and age-related inequities in outcomes. Advances in pathobiology highlighted the central role of the airway epithelium, inflammatory cellular ecosystems, microbiome-associated endotypes, mucus-plug biology, and early-life origins of airway remodelling in shaping asthma heterogeneity and progression.
引用
- Miyata, Fukunaga. Contemporary Concise Review 2025: Asthma. Respirology. 2026. PMID: 42386508. doi:10.1002/resp.70270
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。